Front Cover: Development of a Tumor Microenvironment‐Responsive Co(III)‐Chrysin Prodrug: Synthesis, Activation Profiling, and In Vitro Antineoplastic Evaluation (ChemMedChem 20/2025)

The cover art illustrates the Cobalt–Chrysin Prodrug (CCP), engineered for targeted cancer therapy. On the left, cobalt(III) binds to chrysin, masking its cytotoxicity under normal conditions. The right half depicts CCP activation in the hypoxic tumor environment, releasing chrysin, which then interacts with biomolecules in cancer cells to generate reactive oxygen species (ROS) and induce apoptosis. The bright bursts symbolize selective cancer cell death, highlighting CCP′s potential as a promising anticancer therapeutic for tumor-specific destruction. More details can be found in the Research Article by Rakesh Kumar Pathak and co-workers (DOI: 10.1002/cmdc.202500232).